CD146 (C1C3)

SKU: AP10033CL Category:


For in vitro diagnostic use.

AP10029 (7 mL). Prediluted antibodies in a synthetic organic linear polymer buffer solution (pH 7.4), with carrier protein and preservative for stabilisation “READY TO USE”

AP10029C (1 mL), AP10029CM (0.5 mL), AP10029CL (0.1 mL). Concentrated antibodies with carrier protein and preservative for stabilisation.


For in vitro diagnostic use.

AP10029 (7 mL). Prediluted antibodies in a synthetic organic linear polymer buffer solution (pH 7.4), with carrier protein and preservative for stabilisation “READY TO USE”

AP10029C (1 mL), AP10029CM (0.5 mL), AP10029CL (0.1 mL). Concentrated antibodies with carrier protein and preservative for stabilisation.



The gene product HER-2/neu (also known as c-erbB-2 gene product, p185 or CD380) belongs to the protein family of epidermal growth factor receptors. It is a 185 kDa transmembrane glycoprotein with tyrosine kinase activity. The antibody clone CB11 is directed against the internal domain of the oncoprotein.

Some adenocarcinomas, including carcinomas of the gastrointestinal tract and ovarian carcinomas as well as up to 30% of all breast carcinomas, are showing an overexpression of HER2. It was shown that overexpression of HER2 is correlated with bad prognosis. Similar observations were made for osteosarcomas as well as stomach and bladder carcinomas. It was shown that overexpression of Her2 is correlated with bad prognosis. Since the HER2 protein was identified as major diagnostic target the immunohistochemical determination of HER2 has gained great importance. It was reported by different research groups that 15-30% of all invasive ductal breast carcinomas as

well as 90% of ductal breast carcinomas in situ (DCIS) stain positive for HER2. Proof of HER2 overexpression in breast carcinoma is regarded to be necessary for a therapy with Trastuzumab (Herceptin™).

Immunohistochemistry (IHC) is a complex technique in which immunological and histological detection methods are combined. In general, the manipulation and processing of tissues before immunostaining, especially different types of tissue fixation and embedding, as well as the nature of the tissues themselves may cause inconsistent results (Nadji and Morales, 1983). Endogenous pseudoperoxidase and peroxidase activity or endogenous biotin and alkaline phosphatase activity can cause non-specific staining results depending on the detection system used. Tissues that contain Hepatitis B surface antigen (HBsAg) can produce false positives when using HRP detection systems (Omata et al, 1980). Insufficient contrast staining and/or improper mounting of the sample may influence the interpretation of results.

Isotype: IgG1

Immunogen: Synthetic peptide corresponding to the intracellular domain of human HER2/neu protein.

Staining pattern: Cell membrane.

The interpretation of the stain results is the full responsibility of the user. Any experimental result must be confirmed by a medically established diagnostic product or procedure.

Positive control: Tissue sample from breast carcinoma.

External negative control: Tissue sample homologous to the test sample incubated with an antibody isotype not specific for HER2.



This antibody is designed for the specific localization of human HER2 using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.

This antibody is recommended to determine the levels of expression of the oncoprotein c-erbB-2 in adenocarcinomas of breast, lung and other locations and transitional cell carcinomas of the urinary tract. Immunohistochemical staining of this oncoprotein is associated with gene amplification. In the case of breast cancer, overexpression of this oncoprotein has been shown to be associated with a worse prognosis.



Mouse IgG1 immunoglobulin, clone CB11, obtained from culture supernatant. The preparation contains saline buffer, stabilising and carrier proteins, and sodium azide as a preservative.



Principles of the procedure: The demonstrations of antigens by IHC is a sequential procedure with several steps involving first the application of a specific antibody for the antigen of interest (primary antibody), then a secondary antibody which joins to the first, an enzyme complex, and the addition of a chromogenic substrate. The sample is washed between each step. Enzymatic activation of the chromogenic substrate creates a visible product where the antigen is located. The results are interpreted using a light microscope. The primary antibody can be used both in manual IHC and with automated immunostainers.

Specimen: Paraffin-embedded tissue samples should be used. Western blot techniques are not recommended.

Staining procedure:


Antigen retrieval HIER Citrate Buffer pH 6.0
Working dilution

(only for concentrates)

1:25 – 1:100
Incubation 30-60 min; RT
Control Tissue Breast carcinoma with overexpression of c-erbB-2


Amplification and development of the immunostaining: Follow standard procedure and the recommendations given by the manufacturer for the materials used. In the case of using automated immunostainers, use the specified buffers and materials for each instrument.

See our web site at for detailed protocols, ancillary reagents and support products.



All reagents, materials, and laboratory equipment for IHC procedures are not provided with this antibody. This includes adhesive slides and cover slips, positive and negative control tissues, Xylene or adequate substitute, ethanol, distilled H2O, heat pretreatment equipment (pressure cooker, steamer, microwave), pipettes, Coplin jars, glass jars, moist chamber,

histological baths, negative control reagents, counter-staining solution, mounting materials, and microscope.

Buffered solutions for antigen retrieval, enzyme treatments, highly sensitive detection systems, and other auxiliary reagents are available from Gennova Scientific.



Store at 2-8 °C until the expiration date printed on product label. Do not use after the expiration date. If fresh solutions are required, these must be prepared immediately prior to use, and will be stable for at least one day at room temperature (20-25°C). Unused portion of antibody preparation should be discarded after one day. If the product is stored under different conditions from those stipulated in these technical indications, the new conditions must be verified by the user.

Gennova Scientific guarantees that the product will maintain all of the described characteristics from the production date until the expiration date, as long as the product is stored and used as recommended. No other guarantees are provided. Under no circumstances is Gennova Scientific obliged to cover damages caused by use of this reagent.



If unusual staining is observed or any other deviations from the expected results, please read these instructions carefully, along with the instructions from the detection system. If this does not solve the problem, please contact Gennova Scientific’s technical support department or your local distributor.



Use only by qualified personnel.

Use proper protective equipment in order to avoid contact with reagents and samples in the eyes, skin, and mucosal tissues. In case of contact with sensitive areas, immediately flush the affected area with water. Avoid microbial contamination of the reagent, as this may produce nonspecific staining results. This antibody contains sodium azide (NaN3), used as a stabilising agent, which is not considered to be a hazardous material in the concentration used. Concentration of sodium azide in drainage pipes made of lead or copper can cause the formation of highly explosive metallic azides. In order to avoid this, sodium azide must be disposed of along with a large volume of running water. Material safety data sheet (MSDS) for pure sodium azide is available upon request.



Gennova Scientific has performed studies to evaluate the functioning of these antibodies for use with standard detection systems, concluding that the product is both specific and sensitive for the antigen of interest.




Wright C et al. Cancer Res 49:2087-2090, 1989

Kruger S et al. Int J Cancer 102:514-518, 2002